CD38 and plasma cell myeloma: The mechanisms of action of isatuximab are immune-mediated effects, such as complement- or antibody-dependent cell-mediated cytotoxic effects, antibody-dependent cell phagocytic activity, depletion of CD38-positive regulatory immune cells, and direct killing activity of antibodies against myeloma cells [8–11].